Streetbeat News

Equity Actions

PLD

Prologis (NYSE:PLD) has seen a 15.75% increase in short interest since its last report, with 11.74 million shares sold short, representing 1.47% of its float. The short interest is lower than its peer group average of 4.72%. While an increase in short interest can indicate bearish sentiment, it does not necessarily predict a near-term price drop.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:15 pm

RVTY

Revvity (NYSE:RVTY) has been evaluated by 7 analysts over the last three months, with a mix of bullish to bearish sentiments. The average 12-month price target is now $112.29, down from $131.33, with a high estimate of $135.00 and a low of $95.00. Analysts from firms like Evercore ISI Group, Wells Fargo, Raymond James, Goldman Sachs, Keybanc, and JP Morgan have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Revvity operates in diagnostics and discovery/analytical solutions, serving various markets. Financially, the company has a lower market cap compared to industry averages, a negative revenue trend, a high net margin, but lower ROE and ROA than industry benchmarks, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:01 pm

RYTM

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been the subject of diverse analyst opinions over the past three months, with 7 analysts offering ratings that range from bullish to indifferent. The average 12-month price target for RYTM has increased by 21.7% to $44.86, with a high estimate of $55.00 and a low of $29.00. Analysts from firms including Needham, Morgan Stanley, Wells Fargo, and Goldman Sachs have raised their price targets for RYTM, reflecting a positive outlook on the company's performance. Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare diseases, with setmelanotide (RM 493) as its lead product candidate. The company has shown a significant revenue growth rate of 425.3% as of September 30, 2023, but has a net margin of -196.25% and an ROE of -23.26%, indicating challenges in profitability and equity returns.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:01 pm

CI

Analysts have provided varied ratings for Cigna Group (NYSE:CI) over the last quarter, with recent updates showing a mix of 'Maintain', 'Raise', and 'Outperform' recommendations. The average 12-month price target for CI has increased to $340.43, up from $324.00, with a high estimate of $372.00 and a low of $327.00. Cigna's financials indicate strong market presence, revenue growth, and efficient cost management, with a market cap above industry benchmarks, a positive revenue trend, and a net margin of 2.87%. The company's ROE and ROA also surpass industry standards, and it has a conservative debt-to-equity ratio of 0.68.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

ADI

An analysis of Analog Devices (ADI) compared to its peers in the Semiconductors & Semiconductor Equipment industry reveals mixed signals. ADI's P/E, P/B, and P/S ratios suggest undervaluation, while its ROE, EBITDA, gross profit, and revenue growth indicate potential underperformance. ADI's lower debt-to-equity ratio compared to its top 4 peers suggests a stronger financial position. The industry average P/E is 105.91, P/B is 8.05, P/S is 8.98, and ROE is 7.19%, with an average revenue growth of 7.9%.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

ADBE

The article provides an in-depth comparison of Adobe (NASDAQ:ADBE) against its competitors in the Software industry, analyzing financial metrics such as P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Adobe's P/E ratio is below the industry average, suggesting growth potential, while its P/B ratio indicates potential undervaluation. However, a high P/S ratio could imply overvaluation in sales performance. Adobe's ROE is below the industry average, suggesting inefficiency, but its EBITDA and gross profit are significantly above the industry average, indicating strong profitability. The company's revenue growth is lower than the industry average, pointing to a sales expansion slowdown. Adobe's lower debt-to-equity ratio compared to its top 4 peers suggests a strong financial position with less reliance on debt.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

OPK

OPKO Health Inc (NASDAQ:OPK) stock plummeted by 26.3% to $1.10 after announcing a private offering of $200 million in Convertible Senior Notes due 2029, with an additional option for $30 million. The notes will pay interest semiannually and are convertible under certain conditions. Affiliated entities of key executives are interested in acquiring $70 million of the notes. Proceeds will be used to repurchase common stock and 4.50% Convertible Senior Notes due 2025, with the rest for general corporate purposes.

Portfolio Pulse from Henry Khederian

January 04, 2024 | 3:50 pm

PSX

Phillips 66 is engaged in active discussions regarding the sale of assets worth $3 billion, as revealed at the GS Energy Conference.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:46 pm

CXM

Sprinklr's stock is trading higher following the announcement of a $100 million stock buyback program and the reaffirmation of its Q4 and FY24 guidance. Additionally, Trac Pham has been appointed as the interim COO.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:36 pm

AMD

NVDA

SPOT

Morgan Stanley Wealth Management has adjusted its portfolio by adding a position in Spotify Technology SA (SPOT), increasing its position in NVIDIA Corp (NVDA), and reducing its position in Advanced Micro Devices (AMD).

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:31 pm